Host immune responses limit the duration of expression of transgenes introduced by recombinant adenoviruses
Introduction
Recombinant adenoviruses are highly effective gene transfer vehicles to the liver in vivo. Following intravenous injection, adenovirus serotype 5 (Ad5) preferentially localizes to the liver in rodents. 1, 2 We and others have shown that adenovirus-mediated gene transfer results in transgene expression in the liver at a level that is sufficient for correcting the inherited deficiency of many hepatic enzymes. 3 In particular, we have charac-transfer upon readministration of the vector. 12 Furthermore, cytotoxic lymphocytes (CTL), directed to adenoviral proteins are generated, resulting in hepatic inflammation response, particularly upon secondary administration of the vector. Thus the high efficiency of adenoviral vectors could be utilized fully if the host immune response to the viral antigens could be abrogated.
Studies in nude and SCID mice with defects in T, or in both T and B cell functions, have shown that, in the absence of an immune response transgene expression can persist for approximately 26 weeks. 13 Several approaches have been explored for minimization of the host immune response to the adenoviral vectors. One group of strategies aimed at tolerization of the host to adenoviral antigens involves modification of the host immune system. Administration of adenoviral vectors in neonatal rats, 4, 14 intrathymic injection of adenoviral proteins 5 or oral administration of small doses of adenoviral proteins 6 have resulted in tolerization of rodents to adenoviral antigens, permitting repeated gene transfer. A second group of strategies involve modification of the viral vector. Recombinant adenoviral vectors are generated by disrupting the E1A region of the adenoviral genome, which encodes transcription factors that control viral gene expression and replication and inserting the target gene into the E1A/E1B region 15 However, even in the absence of the E1 proteins, some degree of expression of the viral structural genes takes place in the host cells. To prevent viral gene transcription, vectors have been generated which contain mutations within the E2A region or in all viral genes. 16 However, although these 'gutless vectors' result in prolonged gene expression, repeated gene delivery with these vectors has not been possible, probably because antigens present in the packaged recombinant adenoviruses are sufficient to initiate the primary immune response, resulting in an effective secondary response upon readministration of the virus. 17 Therefore, attempts have been made to prevent the initiation of the primary immune response.
Antibodies produced against recombinant adenoviruses are of the mature IgG isotype, indicating that the B cells that secrete these antibodies have matured via T cell help. Initiation of such mature humoral immune response to an antigen requires costimulatory interactions between CD4
+ T cells and antigen presenting cells (APC). Following binding of the peptide-MHC complex at the APC surface membrane with T cell receptors, costimulation occurs via two well-characterized receptor/ligand molecule pairs, B7/CD28 and CD40/CD40L. CD80 (B7-1) and CD86 (B7-2) molecules on the surface of activated APC or B cells interact with CD28 on the T cell surface, 18 signaling pathways that promote T cell survival. This interaction also up-regulates the expresson of CD40L (CD154) by T cells. Interaction of CD40L with CD40 on the APC surface induces MHC and B7 production by APC and signals the secretion of inflammatory cytokines. 19 The CD40L also interacts with CD40 on the B cell surface, resulting in B cell proliferation, formation of germinal centers, immunoglobulin isotype switching and formation of memory B cells. 19 Thus, the CD28/B7 interaction plays a central role in the initiation of immune response. Two to 3 days after activation, the T cells produce CTLA4 (CD152), which has a higher affinity for B7 molecules than does the CD28. The resulting inhibition of the costimulatory interaction between B7 and CD28 molecules terminates T cell activation. 20 A recombinant soluble CTLA4 (CTLA4Ig) has been generated as a fusion product of the extracellular domain of murine CTLA4 with the murine IgG2a Fc domain 21 CTLA4Ig blocks the costimulatory interaction between CD28 and B7, thereby preventing the initiation of humoral and cell-mediated immune response. Intravenous injection of CTLA4Ig alone at the time of injection of a recombinant adenovirus failed to permit gene transfer after secondary administration of the vector. 22 Even with the simultaneous administration of CTLA4Ig with a monoclonal antibody against the CD40 ligand, secondary gene transfer with an adenoviral vector was possible only in about 50% of cases. 22 Systemic administration of CTLA4Ig and anti-CD40L antibody, along with intratracheal co-administration of two adenoviruses expressing CTLA4Ig and a reporter gene prolonged alveolar transgene expression to 90 days and resulted in transgene expression after a second intratracheal adenovirus administration. 23 However, antibodies were detected in the plasma in 90 to 102 days after the first virus administration and within 21 days after the second administration. We hypothesized that the failure to prevent the immune response fully was related to the unavailability of adequate concentrations of CTLA4Ig at all sites of T cell-APC interaction. Although the two vectors had been injected together, all cells infected by the marker gene vector might not have been infected by the CTLA4Ig-expressing vector, which could have led to immune initiation, albeit in a delayed manner. We hypothesized that if CTLA4Ig could be expressed in all cells infected by the recombinant adenovirus, initiation of humoral and cell-mediated immune response would be blocked more effectively, permitting repeated gene transfer without an immune response against the vector. To test this hypothesis we generated a recombinant adenovirus expressing both CTLA4Ig and human UGT1A1, and characterized the transgene expression and immunological consequences of this vector in Gunn rats.
Results

Prolonged expression of CTLA4Ig
In rats in groups A and B, the maximum serum concentration of CTLA4Ig was reached in 7 days after the first injection (1.8-2 mg/ml). The serum concentration of CTLA4Ig decreased gradually, but it was still detectable at 200 g/ml on day 180. Serum levels reached peak level again on day 362, which was 7 days following the second injection ( Figure 1 ).
Prolonged persistence of the transgene transferred via Ad-hUGT1A1-CTLA4Ig
Southern blot analysis showed that human cDNA sequence was detectable in the DNA extracted from Gunn rats in group A and B for up to 26 weeks after the first injection ( Figure 2a, lanes 2-4) of Ad-hUGT1A1-CTLA4Ig , but not after 50 weeks (Figure 2a, lane 5) . These rats received the second dose on day 355. Liver biopsy 7 days after the second injection showed that human UGT1A1 cDNA was detectable again (Figure 2a , lane 6). Two Gunn rats in group A received a third injection of Ad-hUGT1A1-CTLA4Ig, 280 days after the second injection. Biopsies taken 1 month after the third injection were positive for UGT1A1 cDNA to approximately the same extent as that seen after the first two injections (not shown in Figure 2a ). In contrast, the transgene became undetectable in 10 weeks in the livers of rats in groups C and D after first injection of Ad-hUGT1A1. The transgene was not detectable in the biopsy specimens taken 7 days after the second injection (not shown).
Prolonged expression of human UGT1A1 after injection of Ad-hUGT1A1-CTLA4Ig
Immunoblot analysis: Immunoblot analysis of liver biopsy specimens from rats in group A and B on day 2 and weeks 2 and 26 after the first injection of AdhUGT1A1-CTLA4Ig was positive for a 52 kDa immunoreactive human UGT1A1 band ( Figure 2b, lanes 2-4) . On week 50, the immunoreactive band was not detectable (Figure 2b , lane 5). However, 7 days after the second injection of the virus a strong immunoreactive band was Gene Therapy detectable again (Figure 2b , lane 6). Two Gunn rats received a third dose of Ad-hUGT1A1-CTLA4Ig 40 weeks later. One month after the third injection, the immunoblot was positive for UGT1A1 (not shown). In contrast, in rats in group C and D, the immunoreactive band was detectable up to 10 weeks after the first injection, but not at the later time-points. In this group, the immunoreactive band did not appear in the liver biopsy specimens 7 days after the second injection (not shown).
Immunohistochemistry: The liver samples from groups A and B (Figure 3 , panels a and b) showed high expression of hUGT1A1 after the first and second injection of AdhUGT1A1-CTLA4Ig. In contrast in groups C and D (Figure 3 , panels c and d) the hUGT1A1 expression was observed only after first injection but not after second injection of h-UGT1A1.
Transgene expression after tertiary administration of AdLacZ in rats that had received two previous injections of Ad-hUGT1A1-CTLA4Ig
To determine whether rats receiving repeated injections of a CTLA4Ig-expressing adenovirus can still exhibit transgene expression after administration of a first generation adenovirus, we injected 5 × 10 5 p.f.u. Ad-LacZ, 60 days after the second Ad-hUGT1A1-CTLA4Ig injection (group B). Ten days later, histochemical staining of cryostat sections showed that nearly all hepatocytes expressed bacterial ␤-galactosidase activity ( Figure 3 , panel f). In contrast, rats that received Ad-LacZ injection following two doses of Ad-hUGT1A1 (group D), less than 2% of the hepatocytes stained positive for ␤-galactosidase ( Figure 3 , panel e).
Serum bilirubin levels
Serum bilirubin concentrations were measured every 7-14 days after administration of the recombinant viruses. Both Ad-hUGT1A1-CTLA4Ig (groups A and B) and AdhUGT1A1 (groups C and D) showed marked reduction of mean serum bilirubin levels from pre-injection levels of 8.0 mg/dl to 0.48-0.6 mg/dl in 3 days ( Figure 4 ). In Ad-hUGT1A1-CTLA4Ig-injected rats, serum bilirubin levels increased slowly after 35 days, but remained below 50% of pre-injection levels for 6 months and then progressively increased to 7.5 ml/dl by day 350. A repeat injection of the Ad-hUGT1A1-CTLA4Ig virus on day 355 resulted in a rapid decrease in serum bilirubin concentrations of a magnitude similar to that seen after the first injection ( Figure 4 ). Two of these rats were followed for a further 40 weeks. At that time-point, their serum bilirubin levels had increased to 3.1 and 3.5 mg/dl, respectively. After a third Ad-hUGT1A1-CTLA4Ig injection, the serum bilirubin levels were reduced to 0.4 and 0.3 mg/dl (not shown in Figure 4 ). In rats receiving the first generation adenovector, Ad-hUGT1A1 (groups C and D), serum bilirubin levels began to increase within 28-35 days, reached approximately the pre-injection levels in 175 days. More significantly, the serum bilirubin concentrations did not decline after re-injection of the virus ( Figure 4 ).
Excretion of bilirubin glucuronides in bile
HPLC analysis of bile collected from two rats in group A, 28 days after the second injection (day 362), showed excretion of bilirubin monoglucuronide and diglucuron-
Figure 3 Immunohistochemistry. Human UGT1A1 expression was studied in group A, B, C and D after first and second injections. Representative sections of liver tissues from the various groups are shown. Panels a and b, after first and second injection of Ad-hUGT1A1-CTLA4Ig, respectively. Panels c and d show the expression of UGT1A1 after first and second injections of hUGT1A1, respectively. Panels e and f, injection of Ad-LacZ after tertiary administration of Ad-LacZ in rats that had received two previous injections of Ad-hUGT1A1 (group D) and Ad-UGT1A1-CTLA4Ig (group B), respectively.
Figure 4 Serum bilirubin levels. Both Ad-hUGT1A1-CTLA4Ig (groups A and B -᭛-) and Ad-hUGT1A1 (groups C and D, ¼----¼)
showed marked reduction of mean serum bilirubin levels after first injection. However, after the second injection only the rats that received Ad-hUGT1A1-CTLA4Ig showed significant reduction of bilirubin level.
ide in bile. The HPLC profile was virtually identical to that observed in normal Wistar-RHA rats in that the two glucuronides accounted for more than 95% of the bile pigments, and less than 5% was unconjugated bilirubin. In contrast, in group C, bile pigment analysis following the second injection showed no significant conjugated bilirubin excretion in the bile.
Antibody response
Total IgG antibodies against adenoviral antigens in the sera of rats in various groups was determined by ELISA. Rats receiving Ad-hUGT1A1 (group C and D) showed high titers of antiadenoviral antibodies 3 weeks after both the first (1: 2 11 ) and second (1: 2 12 ) virus administrations. In contrast, antibody titers were negligible in rats in groups A, 3 weeks after the first, second or third injection, and rats in group B, 3 weeks after the first and second injection of Ad-UGT1A1-CTLA4Ig. To determine whether rats that had previously received a CTLA4Ig-expressing adenovirus would retain the capacity to mount an antibody response against adenoviral antigens, rats in groups B and D (that had received Ad-hUGT1A1-CTLA4Ig or AdhUGT1A1, respectively) were injected with Ad-LacZ, 8 weeks after the second injection. Two weeks after the Ad-LacZ injection, antibody titers increased to 1:2 10 in group B and 1:2 14 in group D (Figure 5a) .
To determine the titer of neutralizing antibodies against recombinant adenoviruses, we determined the dilution of sera from treated rats that inhibited the infection of cultured 293 cells by Ad-LacZ. Three weeks after the first injection of Ad-hUGT1A1 (group C), the mean neutralizing antibody titer was 1:2 11 . The titers increased to 1:2 12 , 3 weeks after the second injection. In contrast, in the Ad-hUGT1A1-CTLA4Ig injected rats (group A), neutralizing antibodies were undetectable 3 weeks after the first and the second injection. Two weeks after the injection of Ad-LacZ in animals in groups B and D that had received two previous injections of Ad-hUGT1A1-CTLA4Ig and Ad-hUGT1A1, neutralizing antibody titers of 1:2 10 and 1:2 14 were observed (Figure 5b ).
Marked attenuation of adenovirus-specific CTL response
Capability of the lymphocytes from the treated rats to damage Ad-LacZ-infected primary rat hepatocytes was evaluated by measuring ALT in the media. Lymphocytes from Ad-hUGT1A1-injected rats resulted in the release of 400 and 450 units of ALT into the media after first and second injection (Figure 6a ). In contrast, lymphocytes from animals infected with Ad-hUGT1A1-CTLA4Ig Gene Therapy caused the release of a negligible amount of ALT in the media. After the third injection of Ad-LacZ in groups B and D 400 IU and 500 IU of ALT were released in the media, respectively (Figure 6a ). Cell-mediated immune response to adenoviral antigens was also determined by measuring the secretion of IFN-␥ by stimulated lymphocytes upon exposure to the adenoviral antigens. Four rats injected with Ad-hUGT1A1 (group C) were tested for IFN-␥ secretion into the media by cultured splenocytes, after the first and the second virus administration. In this group, the mean IFN-␥ concentration in the media was 1200 pg/ml and 1350 pg/ml 3 weeks after each injection. In contrast, Ad-UGT1A1-CTLA4Ig injected rats (group A) had very low IFN-␥ concentration in the media (Ͻ100 pg/ml). Rats in group B and D received a third injection with Ad-Lac-Z after two injections of Ad-hUGT1A1-CTLA4Ig and Ad-hUGT1A1. Two weeks after the tertiary challenge, CTL response was shown by release of IFN-␥ into the media at 1200-1350 pg/ml in group B and D (Figure 6b ).
Liver histology
Liver biopsies from rats from group C 3 weeks after the first injection of Ad-hUGT1A1 showed mild periportal infiltration (grade 1 liver damage). However, after the second injection of Ad-hUGT1A1, there was more significant hepatic damage (grade 3-4), including piecemeal necrosis, bridging necrosis and appearance of condensed eosinophilic cells with nuclear fragmentation (Councilman-like bodies), indicating a marked increase in apoptosis (Figure 7a) . In sharp contrast, liver biopsy specimens from rats that received one or two injections of Ad-hUGT1A1-CTLA4Ig, there was no hepatic infiltration, hepatocellular collapse or evidence of increased apoptosis (Figure 7b ). Rats that received Ad-LacZ following two injections of Ad-hUGT1A1-CTLA4Ig (group B), showed a minimum degree of hepatic inflammatory response, similar to that seen after the first injection of Ad-UGT1A1. The two Gunn rats in group A that received a third injection of Ad-hUGT1A1-CTLA4Ig, exhibited no histomorphological features of hepatic inflammation. Serum ALT levels ALT levels in naive Gunn rats ranged from 60 to 70 IU. After the first dose of Ad-hUGT1A1 (group C and D), the levels increased to 165 + 10 IU (n = 10; mean + s.d.). After the second injection in these groups, the ALT levels increased to 300 + 20 IU (n = 10). In contrast, there was no significant change in serum ALT levels in rats after the first or second injection of Ad-hUGT1A1-CTLA4Ig in groups A and B (65 + 7 IU; n = 10). Two rats in group A that received a third injection of Ad-hUGT1A1-CTLA4Ig, the ALT levels remained normal (62 and 66, respectively). In rats receiving Ad-LacZ as the third injection (group B), serum ALT levels increased to 170 + 15 IU (n = 5). In contrast there was no increase of serum ALT levels (62 and 70 IU) in the two rats that were given a third injection of Ad-hUGT1A1-CTLA4Ig (group A).
Discussion
We have engineered a non-replicating recombinant adenovirus that expresses high levels of murine CTLA4Ig and human UGT1A1 from two separate CMV promoters. The marked abrogation of both humoral and cell-mediated immune response to adenoviral antigens after administration of this virus reflects blockade of the B7/CD28 costimulatory pathway. As the B7/CD28 interaction leads to induction of the CD40L in T cells, blockade of the B7/CD28 should be expected to interfere with both of the major costimulatory pathways. However, Kay et al reported that although intravenous administration of CTLA4Ig alone prolonged the expression of transgenes delivered via adenoviral vectors, the recipient mice developed neutralizing antibodies in 16-18 weeks. CTLA4Ig alone did not permit repeated gene expression using these vectors. 22, 23 Even with the simultaneous administration of CTLA4Ig and an antibody against CD40L, secondary gene transfer was possible in some but not all mice, and neutralizing antibodies developed in all mice within 2 weeks of the second vector administration. 22 When in addition to systemic administration of CTLA4Ig and an antibody against CD40 L, a CTLA4Ig-expressing adenovirus was coadministered into the bronchus with a LacZ-expressing adenovirus, plasma antibody response was delayed, but not abrogated. Similarly, the CTL response was reduced but not ablated. After a secondary virus administration there was immune response within 21 days. The failure to abrogate the immune response to the second adenovirus administration could be related to the fact that, in contrast to the immune response to an antigen in a naive animal, memory T cells generated during the initial challenge may be able to produce IL-4 and T helper function after a subsequent challenge without the requirement of CD28/B7 interaction. Therefore, a near-complete inhibition of immune initiation is required for the prevention of a 'booster response' after subsequent antigen administration. When a CTLA4Ig-expressing adenovirus is coadministered with a second adenoviral vector expressing a different transgene, it is unlikely that all cells infected by one virus will be coinfected with the other. This would be particularly true for extrahepatic cells, where the proportion of adenovirally transduced cells is relatively small after systemic administration of the viruses. Therefore, the concentration of CTLA4Ig at some sites of APC-T cell interaction may be inadequate to prevent immune response fully. Our experiments were designed to test the hypothesis that a recombinant adenovirus coexpressing the target transgene and CTLA4Ig should overcome these hurdles, because every cell infected by this vector should express CTLA4Ig. A strong inhibition of the initial immune response should make repeated gene transfer possible.
Southern blot analysis showed that although there was some reduction in the hepatic transgene levels from day 2 to day 14 after the injection of Ad-UGT1A1-CTLA4Ig, the transgene content remained fairly constant between 2 to 26 weeks. However, 50 weeks after the initial injection, the transgene had become undetectable by Southern blot. The persistent and subsequent disappearance of the transgene was paralleled by hUGT1A1 expression, as determined by immunotransblot and the duration of reduction of serum bilirubin levels. Considered together these results suggest that the progressive reduction of transgene expression after 26 weeks resulted from disappearance of the vector from the liver cells, rather than silencing of the CMV promoter. The duration of transgene persistence was similar to that reported in T and B cell-deficient SCID mice. 13 Therefore, it is likely that the eventual attrition of the episomal vector and the transgene expression was not due to host immune response against the adenoviral proteins. This is the first demonstration that a single adenoviral vector co-expressing CTLA4Ig and a target transgene does not evoke humoral or cellular immune response against adenoviral antigens, thereby permitting secondary and tertiary gene transfer using adenoviral vectors. In addition to the immune response to the adenoviral proteins, some transgene products can be immunogenic, 12 although hUGT1A1 did not appear to be immunogenic in rats. It is expected that the CTLA4Ig-coexpressing adenovirus will prevent immune response against the transgene product as well. It should be noted that Ad-UGT1A1-CTLA4Ig produced immune ignorance against the adenoviral antigens, rather than immune tolerance. The ability of the host to mount an immune response to adenoviral antigens was left intact was shown by the development of both humoral and cellular immune response upon administration of Ad-LacZ 2 months after the second injection of Ad-UGT1A1-CTLA4Ig, despite a significant blood level of CTLA4Ig that was expected at that time-point. It appears that the abrogation of humoral and cell-mediated immune response by Ad-hUGT1A1-CTLA4Ig requires a high local (paracrine) concentration of CTLA4Ig in addition to the circulatory levels. This conclusion would be consistent with the observation by other investigators that intravenous injection of CTLA4Ig alone did not prevent the immune response to adenovectors. The effect of CTLA4Ig is in contrast to a permanent state of tolerance that occurs after injection of recombinant adenoviruses in neonatal rats 4 after intrathymic injection of adenoviral antigens 5 or oral tolerization to adenoviral proteins. 6 In each of these cases, first generation adenoviral vectors could be administered repeatedly into rodents without significant immune response.
The non-immunogenic adenoviral vector system described here could have important applications in research. In many cases, the stable expression of a transgene for several months after a single injection and the lack of any detectable hepatic inflammatory response will permit the study of effect of expression of specific genes in experimental animals after birth, without the need for generating transgenic animals. Similarly, antisense RNAs, ribozymes or dominant negative proteins may be generated to down-regulate the expression of specific genes. Furthermore, CTLA4Ig has been used effectively in patients with T cell-mediated diseases, such as psoriasis 24 and in graft-versus-host disease. 25 Therefore, this non-immunogenic vector may have potential application in the treatment of human diseases. In this context it should be noted that CTLA4Ig transgenic mice do not mount an immune response to non-replicating viruses, but retain the capacity to respond immunologically to replicating viruses. 26 Therefore, patients treated with a recombinant adenovirus co-expressing CTLA4Ig could be expected to remain immune-competent against wildtype viruses.
Materials and methods
Animals
Homozygous Gunn rats were bred and maintained in the special Animal core of the Marion Bessin Liver Center of the Albert Einstein College of Medicine. The rats were maintained on standard laboratory chow, and kept in 12-h light/dark cycles. Adult rats of both genders were used for these studies. All animal experiments were performed in conformity with the NIH guidelines and according to a protocol approved by our institutional review board (Animal Research Committee, Albert Einstein College of Medicine).
Generation of Ad-hUGT1A1, Ad-LacZ and AdhUGT1A1-CTLA4Ig
The Ad-hUGT1A1, which expresses human UGT1A1 (previously termed Ad-hBUGT) and Ad-LacZ, which expresses E. coli ␤-galactosidase, were generated from an Ad-5 based vector as described previously. [4] [5] [6] [7] [8] A plasmid containing the full-length cDNA of murine CTLA4Ig downstream to the cytomegalovirus immediate-early promoter-enhancer (obtained from J Bradshaw, Bristol-Meyers Squibb, Princeton, NJ, USA) was partially digested with EcoRI. The CTLA4Ig coding region, along with the CMV promoter was subcloned into the adenovirus shuttle vector p⌬E1sp1A/EcoR1 (Microbix Biosystems, Toronto, Ontario, Canada) in an anti-clockwise direction, generating p⌬E1-CTLA4Ig. The plasmid pcDNA3.1/ Zeo(+)-hUGT1A1, containing the coding region of human UGT1A1 (hUGT1A1) downstream to the CMV promoter was digested with NruI and XbaI. The CMV promoter-hUGT1A1 fragment with a downstream bovine growth hormone polyadenylation signal was isolated and the ends were filled in by incubating with Klenow and dNTPs at 30°C for 30 min. The resulting expression cassette was cloned into the shuttle vector, p⌬E1-CTLA4Ig/SalI in a clockwise direction generating p⌬E1-UGT1A1-CTLA4Ig. The recombinant adenovirus Ad-UGT1A1-CTLA4Ig was generated by recombination following co-transfection of pE1-UGT1A1-CTLA4Ig and pBHG11 into 293 cells as described. 27 Briefly, 293 cells were seeded at 70-80% confluence in six-well plates and transfected for 3 h with 450 l of transfection mixture/well containing 2 g of p⌬E1-UGT1A1-CTLA4Ig, 3 g of pBHGII (containing the E3-deleted adenoviral genome), mixed with Lipofectamine plus (Life Technologies, Rockville, MD, USA). After transfection, the 293 cells were maintained in RPMI 1640 medium with 2% fetal calf serum until a cytopathic effect was observed. Ad-UGT1A1-CTLA4Ig was plaque-purified, and UGT1A1 insertion was confirmed by PCR and CTLA4Ig expression by ELISA. For large-scale preparation, the adenoviruses were grown on 293 cells, which supplies the E1 gene products in trans, allowing the recombinant vectors to propagate. The 293 cells were grown as monolayers in 800 ml triple flasks (Nunc International, Rochester, NY, USA) in DMEM (Life Technologies) supplemented with 10% calf serum. Cells were harvested 48 h after infection and resuspended in 10 mM Tris-HCl (pH 8.0). Recombinant adenoviruses were purified from the cell lysate by two consecutive CsCl density gradient centrifugations on preformed gradients, and stored in 30% glycerol at Ϫ20°C until use within 2 weeks.
To exclude contamination with replication-competent adenoviruses, each batch of recombinant adenovirus was subjected to polymerase chain reaction (PCR) with amplimers designed to amplify the intact E1a region. Only batches that tested negative were used. Plaque-forming units (p.f.u.) of the various batches were determined after infection of immortalized Gunn rat hepatocytes. 28 For Ad-hUGT1A1 and Ad-hUGT1A1-CTLA4Ig, immunocytochemical staining for human UGT1A1 was performed using a monoclonal antibody, WP1. 29 For Ad-LacZ, cytochemical staining was performed for bacterial ␤-galactosidase activity. In all cases, there was 1 p.f.u. per 50-100 viral particles.
Experimental groups
Four groups of Gunn rats (A-D), 250 g of both genders were used. Ten animals in each group, were studied after intravenous injection of virus (6 × 10 11 viral particles). Groups A and B were injected with Ad-hUGT1A1-CTLA4Ig followed by a second Ad-hUGT1A1-CTLA4Ig injection on day 355. Rats in group B received a third injection of Ad-LacZ (6 × 10 11 particles) on day 415. Two rats in group A were injected with a third dose of AdhUGT1A1-CTLA4Ig 635 days after the first injection (ie 280 days after the second injection). For comparison, groups C and D received two injections of Ad-hUGT1A1 (6 × 10 11 viral particles) similarly. Rats in group D received a third injection of Ad-LacZ injection on day 415 (Table 1) .
Determination of serum CTLA4Ig levels
CTLA4Ig levels in serum samples from rats in groups A and B (Table 1) were measured at various time-points after the virus injection by enzyme-linked immunosorbent assay (ELISA) as described previously for mouse sera. 30 In brief, ELISA plates (Nalge Nunc, Naperville, IL, USA)
were coated with anti-murine CTLA4 (PharMingen, San Diego, CA, USA) at 1/500 dilution in PBS overnight at 4°C. The plates were blocked with 5% FCS/3% BSA in PBS, and then incubated sequentially for 1 h at 37°C with serial dilutions of the serum samples followed by horseradish peroxidase-conjugated Fab'2 rabbit anti-mouse IgG2a (Zymed, San Francisco, CA, USA) at 1/8000 dilution in PBS/1% BSA and ABTS substrate (Kirkegaard and Perry, Gaithersburg, MD, USA). Serial dilutions of a known concentration of purified Table 1 Experimental groups
First injection Second injection Third injection (day 1) (day 355 after first injection)
Group A Ad-UGT1A1-CTLA4Ig Ad-UGT1A1-CTLA4Ig Ad-UGT1A1-CTLA4Ig (day 635 after first injection) Group B Ad-UGT1A1-CTLA4Ig Ad-UGT1A1-CTLA4Ig Ad-LacZ (day 400 after first injection) Group C Ad-UGT1A1 Ad-UGT1A1 Group D Ad-UGT1A1 Ad-UGT1A1 Ad-LacZ (day 400 after first injection)
CTLA4Ig were used in each plate to establish a standard curve.
Southern blot analysis for persistence of transgene
Total DNA was extracted from liver biopsy specimens, using the DNeasy Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The DNA specimens (30 g) were digested with EcoRI in the presence of 1% bovine serum albumin overnight. The digested DNA was isolated using a gel extraction kit (Qiagen) according to the manufacturer's instructions and 12 g samples were subjected to electrophoresis on 1% agarose gels. The DNA bands were denatured in gel and transferred on to Nylon membranes. To generate a probe for Southern blot analysis, a plasmid, pSVK3, containing the entire coding region of hUGT1A1 was digested with NotI and XhoI (GIBCO-BRL) and a 2 kb fragment was isolated after agarose gel electrophoresis. The isolated fragment was labeled with using ␣ 32 P-CTP (Amersham Pharmacia), using the Radprime DNA labeling system (GIBCO-BRL). Hybridization was performed at 42°C in the presence of 50% formamide and the bands were visualized by autoradiography.
Immunotransblot analysis of human UGT1A1
Immunoblot analysis was performed as described previously. 26 In brief, tissue homogenates containing 100 g protein per lane were resolved by electrophoresis on SDS-7.5% polyacrylamide gels and electroblotted to nitrocellulose membranes. hUGT1A1 was detected using a monoclonal antibody, WP1, specific for human UGT1A isoforms and a goat anti-mouse IgG FЈab fragment second antibody (Sigma) coupled with horseradish peroxidase. The immunoreactive bands were visualized using an enhanced chemiluminescence system (Pierce, Rockford, IL, USA) according to the manufacturer's protocol.
Expression of human UGT1A1 in Gunn rat liver
Rats were anesthetized with ether and surgical wedge biopsy (50-100 mg) of the liver was performed from two different lobes through a midline incision. Fragments of the wedge biopsy specimens were stored as follows until use: (a) fixed in 10% neutralized formaldehyde for preparation of paraffin sections for histological and immunohistochemical studies; (b) stored at Ϫ80°C for biochemical and molecular analysis; or (c) frozen in tissue freezing medium (Triangle Biomedical Sciences, Durham, NC, USA) on methyl butane baths cooled on dry ice for preparation of cryostat sections.
Immunohistochemical studies
Sections of paraffin-embedded livers were deparaffinized with xylene and rehydrated by incubating successively with 100%, 95%, 70% and 50% ethanol. Endogenous peroxidase was saturated by incubating for 30 min with 3% hydrogen peroxide. The nonspecific sites were blocked with horse serum provided with the Vectastain kit (Vector Laboratories, Burlingame, CA, USA). Endogenous biotin and avidin were blocked using the avidin/biotin blocking kit (Vector Laboratories) according to the instructions of the manufacturer. The slides were then treated with a 1:200 dilution of a polyclonal rabbit antibody raised against a peptide corresponding to a unique region of human UGT1A1. After washing with phosphate-buffered saline, a biotinylated universal secondary antibody provided with the Vectastain kit (Vector Laboratories) was applied. The sections were washed with PBS and overlayed with a streptavidin-peroxidase complex for 5 min. The sections were then treated with the substrate diaminobenzidine tetrahydrochloride. After washing, the sections were counterstained with hematoxylin and mounted for light microscopic examination.
␤-Galactosidase expression
Cryostat sections (5 m) of liver biopsy specimens from rats in groups B and D were fixed at room temperature in freshly prepared 1% glutaraldehyde in PBS for 5 min. ␤-Galactosidase activity was determined by incubating the sections in a staining solution consisting of 5 mM K 4 FeCN 6 , 5 mM K 3 FeCN 6 , 1 mM MgCl 2 , containing 1 mg of 5-bromo-4-chloro-3-indole-␤-galactopyranoside/ml, for 8-15 h at 37°C. The sections were briefly counterstained with eosin, dehydrated, and mounted for light microscopic examination.
Serum bilirubin levels
There were four groups each containing six Gunn rats. These rats were not subjected to liver biopsy. Blood samples (0.5 ml) were collected from the tail vein through a 27 g needle every 15 days. Serum total bilirubin levels were determined by a diazo reagent-based method using a clinical chemistry kit (Sigma), according to the manufacturer's instructions.
Bile pigment analysis
For definitive demonstration of bilirubin glucuronidation, as a terminal experiment in selected rats (two from group A and two from group B, 28 days after the second injection), bile was collected through a polyethylene cannula (PE10) placed in the bile duct. Pigments excreted in the bile were analyzed and quantified by high-pressure liquid chromatography (HPLC) as described previously. 26 Humoral immune response against adenoviral antigens Total IgG antibodies directed against adenoviral antigens and neutralizing antibodies, capable of blocking secondary infection, were determined in serum samples collected at various time-points after each virus administration, as follows.
ELISA for IgG anti-adenoviral antibodies
ELISA for determination of total IgG antibodies directed against adenoviral antigens was performed as described previously. In brief, ELISA plates (Nalge Nunc International) were coated with 5 × 10 8 particles of AdLacZ in PBS overnight at 4°C, blocked with 5% FCS/3% BSA in PBS, and then incubated for 1 h at 37°C sequentially with serial dilutions of the serum samples, a horseradish peroxidase-conjugated Fab'2 rabbit anti-rat IgG-Fc at a dilution of 1/3000 in PBS/1%BSA (Bethyl labrotaries, Montgomery, TX, USA) and the ABTS substrate (Kirkegaard and Perry). Serial dilutions of known concentration of purified rat IgG were used to establish a standard curve.
Neutralizing antibodies against the recombinant adenoviruses
Antibodies capable of blocking subsequent infection by Ad-LacZ was determined as described previously. [4] [5] [6] [7] [8] In brief, 293 cells were plated in 96-well plates at 3 × 10 4 /well, and cultured until 90% confluence. Serum samples were heat-inactivated at 55°C for 30 min and diluted in the medium. Each serum dilution (0.1 ml) was mixed with 7 × 10 6 particles of Ad-LacZ, incubated at 37°C for 90 min, and applied to the nearly confluent 293 cells for 10-12 h. The medium, containing serum and AdLacZ, was then replaced by RPMI, containing 10% fetal calf serum. After 12 h, the cells were fixed and stained for bacterial ␤-galactosidase activity. In the absence of neutralizing antibodies, nearly all of the cells stained blue. The neutralizing antibody titer for each serum sample was reported as the highest dilution at which less than 25% of the cells stained blue.
Cell-mediated immune response against adenoviral antigens
Spleens were harvested at various time-points after the injections. Splenocytes were isolated from selected rats in each group. Red blood cells were removed using lysis buffer containing 8.3 g/liter NH 4 Cl, at pH 7.3 for 10 min. Lymphocytes were pelleted by centrifugation and plated at 5 × 10 7 /5 ml in RPMI with 10% fetal calf serum. The presence of cytotoxic lymphocytes (CTL) directed against adenoviral antigens in the spleen was determined by secretion of interferon-␥ (IFN␥) upon stimulation and by killing of cultured hepatocytes infected with Ad-LacZ, as follows.
Killing of adenovirus-infected hepatocytes
Cytotoxicity of splenocytes isolated from recombinant adenovirus-treated rats against adenovirally infected cultured primary rat hepatocytes was determined as described previously. [4] [5] [6] [7] [8] In brief, the splenocytes were restimulated with Ad-hUGT1A1 for 4-5 days in vitro, and subsequently co-cultured with primary rat hepatocytes Gene Therapy infected with Ad-hUGT1A1 for 5 h at 37°C. Alanine aminotransferase (ALT) released in the media from the rat hepatocytes was measured using a clinical chemistry kit (Sigma). The average value from six wells was used to determine the CTL activity. Maximum possible ALT release from the cells was estimated by incubating the cells with 5 mM D(+)-galactosamine overnight, 4-8 which resulted in ALT levels of 700-900 IU.
Secretion of IFN␥
The splenocytes were restimulated with Ad-hUGT1A1 for 4-5 days as above. The stimulated effector cells were harvested, and the release of ␥-interferon into the media was determined by a sandwhich ELISA (Biosource International, CA, USA) according to manufacturer's instructions. 27 Liver histology To evaluate the degree of hepatic inflammation, fragments of liver biopsy was performed in two rats harvested from each group, 7 days after the second adenoviral infection. Formalin-fixed paraffin sections were stained with hematoxylin-eosin according to standard procedures. The sections were graded for hepatic inflammation as follows: grade 0, normal; grade 1, mild periportal or focal lobular lymphocytic infiltration; grade 2, extension of lymphocytic infiltration into the lobules and 'piece-meal necrosis'; and grade 3, disruption of the lobular architecture by 'bridging necrosis' and extension of lymphocytic infiltrates from portal to central, portal to portal, and central to central zones.
Serum alanine aminotransferase (ALT) levels
As a measure of hepatic inflammation, serum ALT levels were quantified using a clinical chemistry kit (Sigma) as described previously. [4] [5] [6] [7] [8] Briefly, rat serum mixed with alanine ␣␣-KG substrate incubated at 37°C/20 min, then sigma color reagent was added and incubated at RT for 20 min, later mixed with 0.40 N sodium hydroxide and measured OD at 505 nm. ALT levels were expressed in international units.
